ZYXI Stock Overview
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Zynex, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.94 |
| 52 Week High | US$14.75 |
| 52 Week Low | US$6.88 |
| Beta | 0.45 |
| 1 Month Change | -11.42% |
| 3 Month Change | -3.95% |
| 1 Year Change | -2.93% |
| 3 Year Change | -24.93% |
| 5 Year Change | 80.15% |
| Change since IPO | 412.09% |
Recent News & Updates
Recent updates
Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts
Mar 03
Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E
Jan 24Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?
Aug 03Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?
Mar 30Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?
Jan 23Short Squeeze Candidate With Low PEG Ratio: Zynex
Oct 05Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system
Sep 21These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely
Aug 02Zynex Cures The Pain Of Its Shareholders: Q2 Results
Aug 01Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain
Jul 25Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?
Jul 12Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance
Jul 11Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?
Apr 13Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly
Mar 23Zynex: Letter Indicates UnitedHealthcare Is Terminating Contract - An Undisclosed Loss Accounting For 50%+ EBITDA
Feb 17Shareholder Returns
| ZYXI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -4.5% | 1.6% | 1.0% |
| 1Y | -2.9% | -1.4% | 21.9% |
Return vs Industry: ZYXI underperformed the US Medical Equipment industry which returned -1.4% over the past year.
Return vs Market: ZYXI underperformed the US Market which returned 21.9% over the past year.
Price Volatility
| ZYXI volatility | |
|---|---|
| ZYXI Average Weekly Movement | 5.2% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZYXI's share price has been volatile over the past 3 months.
Volatility Over Time: ZYXI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,100 | Thomas Sandgaard | www.zynex.com |
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products.
Zynex, Inc. Fundamentals Summary
| ZYXI fundamental statistics | |
|---|---|
| Market cap | US$349.31m |
| Earnings (TTM) | US$9.73m |
| Revenue (TTM) | US$184.32m |
35.9x
P/E Ratio1.9x
P/S RatioIs ZYXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYXI income statement (TTM) | |
|---|---|
| Revenue | US$184.32m |
| Cost of Revenue | US$38.00m |
| Gross Profit | US$146.32m |
| Other Expenses | US$136.59m |
| Earnings | US$9.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 0.30 |
| Gross Margin | 79.38% |
| Net Profit Margin | 5.28% |
| Debt/Equity Ratio | 124.9% |
How did ZYXI perform over the long term?
See historical performance and comparison